Infinity Pharma (INFI) – Business Wire
-
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
-
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
-
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
-
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
-
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
-
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
-
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with S
-
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
-
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
-
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
-
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
-
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
-
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
-
Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
-
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
-
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
-
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
-
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
-
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
-
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
-
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
-
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
-
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
-
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
-
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium
-
Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
-
Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast
-
Infinity to Participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit
-
Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of Directors
-
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
-
Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)
-
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
-
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update
-
Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials
-
Infinity to Present at The Keystone Symposia Precision Oncology Meeting
-
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
-
Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
Back to INFI Stock Lookup
